"pharmacokinetic - adjusted dosing" for angiogenesis inhibitors
DESCRIPTION
TRANSCRIPT
1
difficult cases in lung cancer- stage III disease -
Dr. med. Wilfried EberhardtDr. med. Wilfried Eberhardt
Head, Outpatient UnitHead, Outpatient Unit
Leader, Thoracic Oncology ProgrammeLeader, Thoracic Oncology Programme
West German Cancer Centre EssenWest German Cancer Centre Essen
Universitätsklinikum EssenUniversitätsklinikum Essen
Hufelandstrasse 55, 45147 EssenHufelandstrasse 55, 45147 Essen
2
difficult cases in lung cancer - stage III
- case focus -
•A 47-year old man, successfully treated with chemoradiotherapy 2 years before for stage IIIB NSCLC, with symptoms of brain metastases
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
3
difficult cases in lung cancer - stage III
- case focus -
• combined modality for stage III
• brain metastases in lung cancer
• chemotherapy for brain mets
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
4
difficult cases in lung cancer - stage III
- case - 1
• 47 year old male smoker
• stage III: upper lobe / right hilar tumor
• comorbidities
– chronic obstructive lung disease ( smoking )
• symptoms
– mild dyspnea
– mild hemoptysis
– cough
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
5 Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
6
difficult cases in lung cancer - stage III
- case - 2
• bronchoscopy : tumor right upper lobe with infiltration of the right tracheobronchial angle and distal end of the trachea
• mediastinoscopy : lymph node metastasis right tracheobonchial, right paratracheal nodes
• histopathology : adenocarcinoma G3
• abdominal CT, brain MRI, bone scan: M0
• staging: T4 N2 M0 = stage IIIB UICC / AJCC
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
7
difficult cases in lung cancer - stage III
- case - 3
Q 1 : How would You treat this patient ?
• radiotherapy alone
• definitive concurrent chemoradiotherapy
• induction chemotherapy and surgery
• induction chemoradiotherapy plus surgery
• palliative chemotherapy alone
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
8
difficult cases in lung cancer - stage III
- case - 4• induction chemotherapy
– 3 cycles cisplatin / paclitaxel
• treatment toxicity and tolerance
– no major side effects
– no nausea and vomiting
– no infection
• treatment response
– decrease of mild dyspnea
– no more mild hemoptysis
– improvement of cough Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
9 Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
10
difficult cases in lung cancer - stage III
- case - 5
• response : minor response ( NC / MR )
• some clinical and symptom improvement
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
11
difficult cases in lung cancer - stage III
- case - 6
• definitive chemoradiation protocol
• 71 Gy ( 45 - 1.5 bid + 36 - 2 qd ) ( 6 weeks )
• one cycle concurrent chemotherapy cisplatin and vinorelbine (week 1 + 2)
• further treatment response
• toxicity mild
– mild pneumonitis
– no further side effects
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
12 Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
13
difficult cases in lung cancer - stage III
- case - 7
• stable clinical situation following definitive chemoradiotherapy for 2 years
• no local relapse
• no systemic relapse outside brain
• excellent life quality, lung function
• after two years follow-up : single event with seizures and headaches
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
14 Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
15 Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
16
difficult cases in lung cancer - stage III
- case - 8
Q 2 : How would You treat the brain metastasis ?
• surgery followed by whole brain radiotherapy
• whole brain radiotherapy alone
• stereotactic radiotherapy
• chemotherapy followed by whole brain radiotherapy
• chemotherapy alone then watch and wait
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
17
difficult cases in lung cancer - stage III
- case - 9
• decision for definitive stereotactic radiotherapy
• single stereotactic radiotherapy treatment
• excellent radiographic response
• no further seizures
• no neurological symptoms
• stable situation for one year
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
18
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
19
difficult cases in lung cancer - stage III
- case - 10
• after one year follow-up : development of headaches
• brain MRI : local progression of metastasis, no new metastatic sites
• chest CT and abominal CT : no local or systemic relapse outside the brain
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
20
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
21
difficult cases in lung cancer - stage III
- case - 11
Q 3 : How would You treat the progression in the brain ?
• surgery followed by whole brain radiotherapy
• re-irradiation ( whole brain or conformal boost )
• stereotactic radiotherapy again
• chemotherapy followed by whole brain radiotherapy
• chemotherapy alone then watch and wait
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
22
difficult cases in lung cancer - stage III
- case - 12
• decision was made to give oral chemotherapy
• patient refused surgical intervention as well as re-irradiation
• oral treatment with temozolomide for five months
• brain MRI : partial stabilization, later again progression
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
23
Eberhardt, Geneva 2007 Eberhardt, Geneva 2007
24
difficult cases in lung cancer - stage III
- case - 13
• after five months oral chemotherapy, again increase of headaches, no seizures
• patient refused surgical intervention as well as re-radiation
• brain MRI : again progression of single met and increase of edema
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
25
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
26
difficult cases in lung cancer - stage III
- case - 14
Q 4 : How would You treat the second brain progression ?
• surgery followed by whole brain radiotherapy
• re-irradiation ( whole brain or conformal boost )
• stereotactic radiotherapy again
• chemotherapy followed by whole brain radiotherapy
• chemotherapy alone then watch and wait
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
27
difficult cases in lung cancer - stage III
- case - 15
• more than three and 1/2 years since intraveneous combination chemotherapy
• decision to give intravenous chemotherapy
• cisplatin and topotecan - one cycle
• chemotherapy well tolerated
• brain MRI : again decrease of met and reduction of edema
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
28 Eberhardt, Geneva 2007 Eberhardt, Geneva 2007
29
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
30
difficult cases in lung cancer - stage III
- final plans for futher management -
• finally : second cycle of systemic chemotherapy for brain metastases
• consolidation radiotherapy planned after the second CTx cycle
• either : conformal stereotactic boost again or whole brain RTx depending on results from brain MRI´s
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
31
• some thoughts.........
Eberhardt et al, Geneva 2007 Eberhardt et al, Geneva 2007
32
• ongoing tumor-free and long-term survival NED
• treatment-induced / toxic event * TOX
• local / locoregional relapse* PD
• systemic relapse outside the brain* PD
• brain relapse PD
• second cancer / second primary SC
• event due to significant comorbidities ††
• ( natural death hazard ) ††
Eberhardt Geneva 2007 Eberhardt Geneva 2007
combined modality therapy for lung cancercombined modality therapy for lung cancer
- competing risks in stage III - - competing risks in stage III -
* Potentially Influenced by chemotherapy
33 Eberhardt Geneva 2007 Eberhardt Geneva 2007
combined modality treatment of stage III NSCLCcombined modality treatment of stage III NSCLC - concurrent and consolidation chemotherapy - - concurrent and consolidation chemotherapy -
Concurrent chemoradiotherapy Consolidation chemotherapy
34
2 x cisplatin/etoposide
IIIA (N2)
CTx : 2 x cisplatin / etoposide
RTx : 61 Gy
combined modality approaches to stage III NSCLCcombined modality approaches to stage III NSCLC - INT 0139 trial study design - - INT 0139 trial study design -
CTx / RTx CTx / RTx
•Albain et al, ASCO 2004 and 2005
Eberhardt Geneva 2007 Eberhardt Geneva 2007
35
observation
3 x docetaxel
randomization IIIB inop
CTx : 2 x cisplatin / etoposideRTx : 61 Gy
combined modality approaches to stage III NSCLCcombined modality approaches to stage III NSCLC - HOG trial study design - - HOG trial study design -
CTx/RTx CTx/RTx CRCRPRPR
NCNC
•Bedano et al, ASCO 2007, abstract 7043 Eberhardt Geneva 2007 Eberhardt Geneva 2007
36 Eberhardt Geneva 2007 Eberhardt Geneva 2007
combined modality treatment of stage III NSCLCcombined modality treatment of stage III NSCLC - induction chemotherapy and concurrent chemoradiotherapy - - induction chemotherapy and concurrent chemoradiotherapy -
Concurrent chemoradiotherapyInduction chemotherapy
37 Eberhardt Geneva 2007 Eberhardt Geneva 2007
author pts
(n)
CTx RTx
(Gy)
LRC
( 3y )
LRC
(5y)
OS
(med)
OS
(1y; %)
ac Tox
(3/4°)
Fournel 2007
64
63
2 x PT ind + 3 x PVrb cc
cc 3 x PVrb + 2 x PTcons
66
66
N/R N/R
19.0
15.7
68.8
57.1
10 E
19 E
multicenter randomized controlled trials in stage IIImulticenter randomized controlled trials in stage III - induction vs consolidation chemotherapy - II- induction vs consolidation chemotherapy - II
E = esophagitis E = esophagitis
38
CTx- CTx- CTx - C/hf-RTx (45 Gy) Restaging operable
(PET-CT) (Angio-CT) (PET)
D E S I G N – N S C L C IIIA / III BD E S I G N – N S C L C IIIA / III B - randomized Phase-III study ESPATÜ - - randomized Phase-III study ESPATÜ -
IIIA IIIB
CTx : Cisplatin (50 mg/m2 T 1+8) / Paclitaxel (175 mg/m2 T 1)C/Hf-RTx : Cis/Nav (50/20 mg/m2 T 2+9) / 1.5 Gy bid/5 x per wk/3 wks = 45 GyB : Boost-C/RTx : Cis/Nav (40/15 mg/m2 T 2+9(Nav)) / 20 or 26 Gy a 2 Gy ( A )T : Thoracotomy ( B )
inoperable B
B
T
isolated brain relapse as first site of failureisolated brain relapse as first site of failure
Eberhardt, Pöttgen 2005 Eberhardt, Pöttgen 2005
0 12 24 36 48 600,00
0,05
0,10
0,15
0,20
0,25
0,30
0,35
0 12 24 36 48 600,00
0,05
0,10
0,15
0,20
0,25
0,30
0,35
with PCI
66
810
1216
1522
2232
patients at risk 51 55
isol
ate
d b
rain
re
laps
e as
firs
t site
of f
ailu
re
months
without PCI
66
810
1216
1522
2232
patients at risk 51 55
isol
ate
d b
rain
re
laps
e as
firs
t site
of f
ailu
re
months
40
International Association for the Study of Lung CancerInternational Association for the Study of Lung Cancerwww.iaslc.org
European Society for Medical OncologyEuropean Society for Medical Oncologywww.esmo.org
American Society of Clinical OncologyAmerican Society of Clinical Oncologywww.asco.org